Robert Dreicer, MD, explains how intensifying treatment through the combination of androgen-deprivation therapy and androgen receptor pathway inhibitors (eg, abiraterone acetate [Zytiga], enzalutamide [Xtandi], and apalutamide [Erleada]) has improved outcomes in patients with metastatic castration-sensitive prostate cancer. Dreicer is deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of medicine and urology, University of Virginia Health System.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.